Loading Pathway...
Error: Pathway image not found.
Hide
Pathway Description
Cocaine Dopamine-reuptake Inhibitor Action Pathway
Homo sapiens
Drug Action Pathway
Cocaine is a local anesthesia and vasoconstrictor that is clinically used during diagnostic proceedures or during surgery in or through the nasal cavity. It comes in drugs called Goprelto and Numbrino which comes as a nasal spray. In these clinical drugs it takes the form of cocaine hydrochloride. The illicit drug has the same effects. It primarily acts on sensory neurons in the nasal cavity, but also inhibits dopamine, serotonin, and norepinephrine re-uptake channels.
This inibition leads to an accumulation in the synapse of these neurotransmitters. For dopamine this leads to activation of dopamine receptors, especially the D2 dopamine receptor which has been implicated in the cause of addiction through the reward pathway. D2 receptors inhibit adenylate cyclase which leads to a lower concentration of cAMP which lowers neuronal excitability. Other dopamine receptors also have an effect on addiction,, especially the D1 dopamine receptor. The exact mechanisms in which D2 receptors cause addiction is unknown. D1 dopamine receptors also have an effect on addiction. They are Gs coupled and activated adenylate cyclase rather than inhibit. D1-D2 dopamine receptor heteromers have also been found to effect addiction, although they have not been researched enough to understand how.
References
Cocaine Dopamine-reuptake Inhibitor Pathway References
Wilson JM, Levey AI, Bergeron C, Kalasinsky K, Ang L, Peretti F, Adams VI, Smialek J, Anderson WR, Shannak K, Deck J, Niznik HB, Kish SJ: Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol. 1996 Sep;40(3):428-39. doi: 10.1002/ana.410400312.
Pubmed: 8797532
Kim DI, Schweri MM, Deutsch HM: Synthesis and pharmacology of site specific cocaine abuse treatment agents: 8-substituted isotropane (3-azabicyclo[3.2.1]octane) dopamine uptake inhibitors. J Med Chem. 2003 Apr 10;46(8):1456-64. doi: 10.1021/jm020410t.
Pubmed: 12672245
Rothman RB, Baumann MH, Dersch CM, Appel J, Houghten RA: Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library. Synapse. 1999 Sep 1;33(3):239-46. doi: 10.1002/(SICI)1098-2396(19990901)33:3<239::AID-SYN8>3.0.CO;2-R.
Pubmed: 10420171
Carrera MR, Meijler MM, Janda KD: Cocaine pharmacology and current pharmacotherapies for its abuse. Bioorg Med Chem. 2004 Oct 1;12(19):5019-30. doi: 10.1016/j.bmc.2004.06.018.
Pubmed: 15351386
Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. doi: 10.1016/s0014-2999(97)01393-9.
Pubmed: 9537821
Verma V: Classic Studies on the Interaction of Cocaine and the Dopamine Transporter. Clin Psychopharmacol Neurosci. 2015 Dec 31;13(3):227-38. doi: 10.9758/cpn.2015.13.3.227.
Pubmed: 26598579
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, Assempour N, Iynkkaran I, Liu Y, Maciejewski A, Gale N, Wilson A, Chin L, Cummings R, Le D, Pon A, Knox C, Wilson M: DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. doi: 10.1093/nar/gkx1037.
Pubmed: 29126136
Highlighted elements will appear in red.
Highlight Compounds
Highlight Proteins
Enter relative concentration values (without units). Elements will be highlighted in a color gradient where red = lowest concentration and green = highest concentration. For the best results, view the pathway in Black and White.
Visualize Compound Data
Visualize Protein Data
Downloads
Settings